Physician profile
Robert M Gold
NPI 1710070750
$4,419.39
in general payments reported to CMS, 2019-2025
26 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $602 · 2021: $1,111 · 2022: $1,009 · 2023: $654 · 2024: $320 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $566.55 | 2019-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $468.87 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $389.67 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $376.18 | 2021-2025 | |
| Daiichi Sankyo INC. | $353.72 | 2019-2023 | Injectafer |
| Amgen INC. | $275.00 | 2019-2023 | Tavneos |
| Veloxis Pharmaceuticals, INC. | $258.67 | 2019-2023 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $237.61 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $204.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $196.38 | 2019-2022 | |
| Vifor Pharma, INC. | $163.65 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $139.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $125.11 | 2020-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $116.47 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $114.31 | 2019-2023 | Rayaldee |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $91.56 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $72.68 | 2021-2023 | Monoferric |
| Genentech USA, INC. | $56.52 | 2019 | |
| Calliditas Therapeutics US INC. | $54.62 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $29.62 | 2022 | |
| Nuwellis, INC. | $25.15 | 2021 | |
| Ani Pharmaceuticals, INC. | $23.29 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.83 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.